World Alzheimer's Day 2008 Special Report: New innovative treatment approaches in Alzheimer's disease which involve mechanisms other than a direct attack on amyloid plaques have emerged as the leading candidates in the fight against Alzheimer's in 2008. These approaches were presented at ICAD 2008, the world's leading forum on dementia research. These new developments are discussed in the debut of AlzheimerVideoNews.com, a new website which takes a critical look at the most important news in Alzheimer's research.
Los Angeles, CA (PRWEB) September 23, 2008 -- AlzheimerVideoNews.com debuts with a World Alzheimer's Day 2008 Special Report, discussing the most significant developments which occurred in 2008 in the field of Alzheimer's disease research. The new report, available in both a video news report and in print at http://www.AlzheimerVideoNews.com [AlzheimerVideoNews.com], discusses several innovative therapeutics which address emerging new targets in Alzheimer's disease. These new therapeutics have taken center stage in 2008, after the prominent failure of the anti-amyloid investigational drugs tramiprosate(Alzhemed®, Neurochem) and Flurizan® (Myriad Genetics).
The promising new therapeutic agents discussed at ICAD 2008, the world's leading forum on dementia research, and in scientific publications in 2008, included the antihistamine Dimebon® (Medivation, now licensed to Pfizer); Rember®, a reforumulation of methylene blue (TauRX Therapeutics of Singapore); and a novel, off-label method of perispinal administration of etanercept. These agents are all hypothesized to address non-amyloid targets, including the tau tangles found in the brain(Rember®).
Among these agents etanercept is unique, because it was designed to correct an abnormality in the immune system, identified in Alzheimer's disease, which may affect brain function. This abnormality, an excess of the molecule TNF in the cerebrospinal fluid, is hypothesized to interfere with brain cell communication in patients with Alzheimer's disease and related forms of dementia.
AlzheimerVideoNews.com takes a critical look at the most important news in Alzheimer's research. The http://www.AlzheimerVideoNews.com [AlzheimerVideoNews.com website] includes links to further reports and discussion regarding recent developments in Alzheimer's research. AlzheimerVideoNews.com is sponsored by http://www.nrimed.com [the Institute for Neurological Research, a private medical group, inc. in Los Angeles], which has developed the perispinal etanercept anti-TNF strategy for dementia.
References: Doody, R.S., S.I. Gavrilova, M. Sano, R.G. Thomas, P.S. Aisen, S.O. Bachurin, L. Seely, and D. Hung, Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study. Lancet, 2008. 372(9634): p. 207-15.
Tobinick, E.L. and H. Gross, Rapid improvement in verbal fluency and aphasia following perispinal etanercept in Alzheimer's disease. BMC Neurol, 2008. 8(1): p. 27.
Read the full story at http://www.prweb.com/releases/Alzheimers/etanercept/prweb1358314.htm
Copyright©2008 Vocus, Inc.
All rights reserved